FDA is requiring weight loss drug makers to add a vision loss warning

The FDA is mandating that manufacturers of GLP-1 weight loss drugs, including Ozempic and Wegovy, add a warning label regarding a rare eye condition called NAION. This decision follows reports of potential vision loss associated with the medication.